Adenylosuccinic acid (Synonyms: Adenylosuccinate; Aspartyl adenylate)

Cat. No.: HY-127137 Purity: 99.74%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD).

For research use only. We do not sell to patients.

Adenylosuccinic acid Chemical Structure

CAS No. : 19046-78-7

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Adenylosuccinic acid:

Adenylosuccinic acid tetraammonium In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vivo

Adenylosuccinic acid (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca²⁺ content of mdx tibialis anterior^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice^[1]
Dosage:	3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL
Administration:	3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks
Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.

Clinical Trial

Molecular Weight

463.29

Formula

C₁₄H₁₈N₅O₁₁P

CAS No.

19046-78-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(C[C@H](NC1=C2N=CN(C2=NC=N1)[C@H]3[C@H](O)[C@H](O)[C@H](O3)COP(O)(O)=O)C(O)=O)O

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (107.92 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1585 mL	10.7924 mL	21.5848 mL
5 mM	0.4317 mL	2.1585 mL	4.3170 mL
10 mM	0.2158 mL	1.0792 mL	2.1585 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (276 KB) SDS (394 KB)

COA (256 KB) HNMR (484 KB) RP-HPLC (206 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1585 mL	10.7924 mL	21.5848 mL	53.9619 mL
	5 mM	0.4317 mL	2.1585 mL	4.3170 mL	10.7924 mL
	10 mM	0.2158 mL	1.0792 mL	2.1585 mL	5.3962 mL
	15 mM	0.1439 mL	0.7195 mL	1.4390 mL	3.5975 mL
	20 mM	0.1079 mL	0.5396 mL	1.0792 mL	2.6981 mL
	25 mM	0.0863 mL	0.4317 mL	0.8634 mL	2.1585 mL
	30 mM	0.0719 mL	0.3597 mL	0.7195 mL	1.7987 mL
	40 mM	0.0540 mL	0.2698 mL	0.5396 mL	1.3490 mL
	50 mM	0.0432 mL	0.2158 mL	0.4317 mL	1.0792 mL
	60 mM	0.0360 mL	0.1799 mL	0.3597 mL	0.8994 mL
	80 mM	0.0270 mL	0.1349 mL	0.2698 mL	0.6745 mL
	100 mM	0.0216 mL	0.1079 mL	0.2158 mL	0.5396 mL

Adenylosuccinic acid Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Adenylosuccinic acid19046-78-7Adenylosuccinate Aspartyl adenylateEndogenous MetaboliteDuchennemusculardystrophyDMDmetabolitenucleotidecycleInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *